News: CTX-derived Exosomes

Further collaborations underway to demonstrate the potential of ReNeuron’s proprietary exosome platform
Emerging data shows platform’s application to a range of novel therapeutics targeting the brain and other tissues

19 March 2021: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, provides an update on the positive progress being made by third party commercial collaborators with its exosome technology platform and the signing of new collaboration agreements with a major pharmaceutical company and leading academic institutions in the UK and mainland Europe.

Read more…

10 September 2020: ReNeuron Group plc (AIM: RENE), a global leader in the development of cell-based therapeutics, is pleased to provide a trading update ahead of today’s Annual General Meeting (“AGM”).

Read more…

25 June 2020: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, today announces that it has signed a new research evaluation agreement with a major US biotechnology company in connection with the use of the Company’s proprietary exosomes for the delivery of novel gene silencing therapeutics.

Read more…

17 June 2020: ReNeuron Group plc (AIM: RENE), a global leader in the development of cell-based therapeutics, provides the following update on its cell-based therapy programmes.

Read more…

07 April 2020: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, today announces that it has signed a research agreement with an unnamed major pharmaceutical company to explore the potential use of the Company’s proprietary exosomes to deliver novel therapeutics.

Read more…

10 September 2019: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to provide a trading update ahead of the Company’s Annual General Meeting (“AGM”) this Thursday.

Read more…

14 August 2019: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to announce that it is partnering with the University of Cardiff under a new grant-funded collaboration utilising ReNeuron’s exosome-based drug delivery technology platform.

Read more…

16 July 2019: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, announces that it has expanded its intellectual property estate via the grant of a number of key patents covering its exosome technology platform.

Read more…

8 May 2019: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, announces a year-end business update ahead of its preliminary results for the year ended 31 March 2019, which will be announced on Thursday 11 July 2019.

Read more…